Product Images Asenapine

Asenapine sublingual tablets, 10 mg strength, that have a black cherry flavor and come in a pack of 60 unit-dose tablets. The medication contains Phenylalanine 0.17 mg per tablet and may not be suitable for individuals with phenylketonuria. Dosage is indicated as sl, but the remaining text is not available due to errors.*

Asenapine sublingual tablets are available in unit-dose blisters each containing 2.5mg of asenapine. The tablets are black cherry flavored and contain phenylalanine. They are recommended for sublingual use only and are available by prescription. The storage temperature should be between 15° - 30°C (58°F - 85°F). The medication should be kept out of reach of children. The dosage information is not provided. Manufacturing and distribution information is difficult to read.*

This is a medication information sheet for Asenapine Sublingual Tablets, 5mg. The tablets are intended for sublingual use and should not be crushed, chewed, or swallowed. The medication contains 0.17mg of phenylalanine per tablet and is flavored with black cherry. The dosage instructions are not available in this text. The medication should be stored at room temperature and kept out of reach of children. This medication is manufactured by a pharmaceutical company named Reckitt Benckiser.*

This text describes the population of a study or clinical trial. It includes information about different levels of renal and hepatic impairment, smoking status, Japanese ethnicity, and pediatrics. The data presented are based on a comparison to reference groups (normal renal and hepatic function, non-smoker, Caucasian adults). The PK parameters Cmax and AUC are also reported, along with fold change and 90% CI.*

The text appears to be a table representing a clinical trial study for Asenapine Sublingual tablets and Placebo. The table shows the number of patients (2 in each group) and their progress over time (in days) until relapse occurs. The product limit estimators are based on the Kaplan-Meier distribution with censoring at the last contact date.*